



PRESS RELEASE

05 August 2024 10:55:00 CEST

AcouSort enters its third collaboration within flow cytometry

Efficient sample preparation is a challenge in flow cytometry and AcouSort is experiencing a growing interest from flow cytometry manufacturers to use the company's unique acoustofluidics technology for establishing swift and automated workflows in sample preparation.

Flow cytometry is an attractive market for AcouSort, and the company is currently exploring how its technology can be paired with flow cytometers to create a cohesive and effective workflow. To this end, AcouSort is now entering a collaboration with one of the leading manufacturers of flow cytometers in Europe.

The collaboration aims to evaluate the acoustic separation technology together with the partnering company's equipment. As a first step in the collaboration, AcouSort will supply the partnering company a dedicated separation test module with associated software as well as an application support package. The revenues generated from this initial phase of the collaboration will be EUR 15,850.

"This new collaboration with a leading manufacturer of flow cytometers based in Europe is very encouraging as it reflects the increasing interest we see in evaluating AcouSort's technology for different applications both within cell therapy production and now also flow cytometry," says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of-Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).